Boston, MA – October 17, 2017 – Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue. Cerevance is exercising an option agreement it previously signed with Rockefeller to license the technology developed in the laboratory of Nathaniel Heintz, Ph.D., the James and Marilyn Simons Professor at Rockefeller, and a Howard Hughes Medical Institute Investigator.
“Nat Heintz and his colleague, Xiao Xu, have invented a powerful technology that Cerevance’s scientists will use to identify target proteins in human brain tissue and advance new therapeutics for neurological and psychiatric diseases,” said Brad Margus, Chief Executive Officer of Cerevance. “The technology enables us to overcome many of the limitations of animal models and human iPSC cells faced in drug discovery.”
“Our institution is always pleased to see its discoveries partnered with robust young companies who can accelerate the development of the technology to improve human health,” said Kathleen Denis, PhD, CLP, Associate Vice President, Office of Technology Transfer at Rockefeller. “Our prior experience with the management team that founded Cerevance was positive, and we believe that they will be a good partner for this technology.”
Cerevance is a recently formed pharmaceutical company focused on central nervous system
diseases. The company’s strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. Its scientists believe that they are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.
Robert Middlebrook, +1-408-220-5722